Viracta Therapeutics Inc Quick Ratio (VIRX) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Viracta Therapeutics Inc   (NASDAQ: VIRX)

Viracta Therapeutics Inc 's Quick Ratio

VIRX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the third quarter 2024, Quick Ratio deteriorated to 0.74 a new company low.

Within Major Pharmaceutical Preparations industry 361 other companies have achieved higher Quick Ratio than Viracta Therapeutics Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 1521 to 1856.

Explain Quick Ratio?
How much Cash & cash equivalents VIRX´s has?
What are VIRX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VIRX Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change -21.56 % 87.85 % 158.04 % 294.26 % 304.36 %
Y / Y Cash & cash equivalent Change -66.43 % -58.82 % -50.75 % -41.03 % -18.32 %
Quick Ratio MRQ 0.74 1.05 1.32 1.4 1.73
VIRX's Total Ranking # 1856 # 1521 # 1524 # 1455 # 1256
Seq. Current Liabilities Change -0.01 % -4.98 % -21.62 % 5.34 % 139.46 %
Seq. Cash & cash equivalent Change -29.57 % -24.16 % -26.31 % -14.71 % -13.61 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 362
Healthcare Sector # 673
Overall Market # 1856


Quick Ratio Statistics
High Average Low
22.34 4.31 0.74
(Mar 31 2021)   (Sep 30 2024)




Financial Statements
Viracta Therapeutics Inc 's Current Liabilities $ 29 Millions Visit VIRX's Balance sheet
Viracta Therapeutics Inc 's Cash & cash equivalent $ 21 Millions Visit VIRX's Balance sheet
Source of VIRX's Sales Visit VIRX's Sales by Geography


Cumulative Viracta Therapeutics Inc 's Quick Ratio

VIRX's Quick Ratio for the trailling 12 Months

VIRX Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth 71.99 % 192.6 % 222.69 % 208.71 % 98.1 %
Y / Y Cash & cash equivalent TTM Growth -53 % -42.05 % -30.92 % -21.43 % -13.7 %
Quick Ratio TTM 1.15 1.4 1.91 2.65 4.21
Total Ranking TTM # 3486 # 3326 # 3406 # 3327 # 3066
Seq. Current Liabilities TTM Growth -5.89 % 11.13 % 18.12 % 39.22 % 60.12 %
Seq. Cash & cash equivalent TTM Growth -22.46 % -18.71 % -15.11 % -12.16 % -4.39 %

Quick ratio ranking by company, industry and sector >> Back to VIRX Financial Strength Comparisons >> Go to Compare VIRX Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in VIRX's Current Liabilities to $28.58 millions, cumulative Quick Ratio to 1.15 below the VIRX average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 446 other companies have achieved higher Quick Ratio than Viracta Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2024 from 3326 to 3486.

Explain Quick Ratio?
How much Cash & cash equivalents VIRX´s has?
What are VIRX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 447
Healthcare Sector # 941
Within the Market # 3486


trailing twelve months Quick Ratio Statistics
High Average Low
16.18 4.52 1.15
(Sep 30 2021)   (Sep 30 2024)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Alkermes Plc   2.00 $ 908.864  Millions$ 453.705  Millions
Organigram Global Inc   2.00 $ 81.767  Millions$ 40.845  Millions
Cue Biopharma Inc   1.93 $ 32.420  Millions$ 16.790  Millions
Kairos Pharma Ltd   1.92 $ 3.217  Millions$ 1.672  Millions
Bridgebio Pharma Inc   1.91 $ 266.324  Millions$ 139.216  Millions
Forte Biosciences Inc   1.91 $ 16.363  Millions$ 8.580  Millions
Summit Therapeutics Inc   1.89 $ 125.997  Millions$ 66.761  Millions
Tonix Pharmaceuticals Holding Corp   1.86 $ 28.233  Millions$ 15.181  Millions
Vincerx Pharma Inc   1.86 $ 10.086  Millions$ 5.424  Millions
Purple Biotech Ltd  1.86 $ 7.401  Millions$ 3.987  Millions
Galectin Therapeutics Inc   1.84 $ 27.060  Millions$ 14.740  Millions
Wave Life Sciences Ltd   1.82 $ 310.948  Millions$ 170.728  Millions
Ironwood Pharmaceuticals inc   1.79 $ 88.211  Millions$ 49.383  Millions
Acurx Pharmaceuticals inc   1.74 $ 5.763  Millions$ 3.319  Millions
Cns Pharmaceuticals Inc   1.72 $ 6.973  Millions$ 4.057  Millions
Gyre Therapeutics Inc   1.71 $ 25.092  Millions$ 14.716  Millions
Cellectar Biosciences Inc   1.69 $ 34.263  Millions$ 20.234  Millions
Tempest Therapeutics Inc   1.68 $ 22.116  Millions$ 13.145  Millions
Moleculin Biotech Inc   1.68 $ 9.405  Millions$ 5.593  Millions
Xilio Therapeutics Inc   1.66 $ 61.259  Millions$ 36.870  Millions
Ptc Therapeutics inc   1.66 $ 1,013.357  Millions$ 610.712  Millions
Acadia Pharmaceuticals Inc   1.64 $ 565.330  Millions$ 343.945  Millions
Vertex Pharmaceuticals Inc  1.64 $ 6,524.500  Millions$ 3,973.100  Millions
Revelation Biosciences Inc   1.61 $ 6.541  Millions$ 4.067  Millions
Prf Technologies Ltd   1.61 $ 4.271  Millions$ 2.656  Millions
Amphastar Pharmaceuticals Inc   1.59 $ 252.691  Millions$ 159.010  Millions
Bioxcel Therapeutics Inc   1.58 $ 40.387  Millions$ 25.557  Millions
Amicus Therapeutics inc   1.58 $ 249.757  Millions$ 158.138  Millions
Spero Therapeutics Inc   1.55 $ 76.290  Millions$ 49.096  Millions
Abivax Sa  1.53 $ 161.528  Millions$ 105.279  Millions

Date modified: 2026-09-08T15:11:23+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.